CD8A and neoplasm: Aside from improving the quality and number of tumor‐infiltrated CD8+ T‐cells, combination therapy also increased the population of inflammatory DC (CD11c+Ly6c+) (Fig. 5I), CD103+ DC (Fig. 5J,K) and XCR1+ DC (Fig. S3C).